Share This Page
Drugs in ATC Class D05
✉ Email this page to a colleague
Up to Top Level ATC Classes
Up to D - Dermatologicals
Subclasses in ATC: D05 - ANTIPSORIATICS
Market Dynamics and Patent Landscape for ATC Class D05 – Antipsoriatics
Executive Summary
The ATC (Anatomical Therapeutic Chemical) Classification System's Class D05 encompasses drugs used primarily for the treatment of psoriasis, a chronic autoimmune skin disorder with significant unmet medical needs. The global market for antipsoriatic agents is experiencing rapid growth, driven by increasing prevalence, novel drug approvals, and advancements in biologic therapies. This comprehensive analysis explores current market trends, competitive landscape, patent activities, and future outlooks, providing actionable insights for stakeholders.
What Are the Market Drivers and Trends for Antipsoriatics (D05)?
Prevalence and Market Drivers
- Global Burden: Approximately 125 million individuals worldwide suffer from psoriasis, with incidence rates rising due to increased urbanization and genetic predisposition (WHO, 2021).
- Advances in Biologic Therapies: Biologics, such as monoclonal antibodies targeting TNF-α, IL-17, and IL-23 pathways, dominate the market due to superior efficacy and safety profiles.
- Untapped Populations: Emerging markets like Asia-Pacific and Latin America exhibit rising demand, driven by increasing awareness and healthcare infrastructure development.
- Patient Preference: Shift towards personalized medicine and topical formulations for mild cases offsets the reliance on systemic drugs.
Technological Progress and Product Pipeline
| Technology/Drug Class | Market Share (2022) | Key Drugs | Notable Innovations |
|---|---|---|---|
| Biologics | ~70% | Adalimumab, Secukinumab, Ixekizumab | Next-gen biologics targeting IL-17A, IL-23p19 |
| Small Molecule Systemics | ~20% | Apremilast, Tofacitinib | Oral formulations, fast-onset |
| Topicals & Biosimilars | ~10% | Calcipotriol, Etanercept biosimilars | Cost-effective options |
Pricing and Reimbursement Trends
- Biologic Costs: High; biologic therapies can cost between $20,000–$50,000 annually.
- Reimbursement Policies: Increasing supplementation in major markets (US, EU, Japan); Biosimilar entry pressures reducing prices.
- Market Access: Price negotiations and patient assistance programs influence uptake patterns.
What Does the Patent Landscape Look Like for D05 Antipsoriatics?
Global Patent Filing Trends (2010–2023)
| Year | Number of Patent Filings | Notable Patent Holders | Focus Areas |
|---|---|---|---|
| 2010-2014 | 215 | Amgen, Novartis, Johnson & Johnson | Biologics, IL-17/23 inhibitors |
| 2015-2018 | 348 | Eli Lilly, AbbVie, Biogen | Biosimilars, oral small molecules |
| 2019-2023 | 425 | AstraZeneca, Pfizer, Samsung Bioepis | Next-gen biologics, formulations |
Source: PatentScope (WIPO), 2023
Key Patent Areas
| Patent Focus Area | Examples | Patent Durations & Challenges |
|---|---|---|
| Biologic Molecules | Secukinumab, Risankizumab | Patent expiry typically ~2030; biosimilar challenges |
| Novel Mechanisms of Action | IL-17A/IL-23 inhibitors | Patents filed through 2025; high entry barriers |
| Drug Delivery Systems | Sustained-release formulations | Patent protection through 2035; formulation complexity |
| Combination Therapies | Topical + systemic agents | Increasingly patent-protected; regulatory hurdles |
Recent Patent Disputes and Litigation
- Key Disputes: Biosimilar litigation around Humira (adalimumab) has influenced patent strategies in antipsoriatic biologics.
- Patent Thickets: Companies pursue broad patents covering formulations, manufacturing processes, and therapeutic uses to deter generic entry.
Patent Cliff Risks and Opportunities
- Upcoming Patent Cliffs: Major biologics' patents, notably Humira, are set to expire by 2023–2025, opening opportunities for biosimilar manufacturers.
- Innovation Drive: Companies innovate through gene therapy, personalized biologics, or novel delivery mechanisms as alternative protection strategies.
How Is the Competitive Landscape Shaping Up?
Major Market Players
| Company | Key Antipsoriatic Drugs | Market Share (Estimate, 2022) | Strategic Focus |
|---|---|---|---|
| AbbVie | Humira, Skyrizi (risankizumab) | ~27% | Biologic portfolio expansion |
| Novartis | Cosentyx (secukinumab) | ~20% | Next-gen biologics |
| Eli Lilly | Taltz (ixekizumab), Olumiant (baricitinib) | ~15% | Small molecules + biologics |
| Pfizer | Xeljanz (tofacitinib) | ~8% | Oral selective JAK inhibitors |
| Samsung Bioepis | Biosimilars to Humira, Enbrel | Emerging | Cost-effective biologics |
Emerging Competitors & Startups
- Focus on biosimilars and innovative oral agents.
- Companies like Coherus, Biogen, and Mabpharm expanding their biologic pipelines.
Market Entry Barriers
- Patent thickets.
- High R&D costs (>USD 1 billion for biologics).
- Complex manufacturing requirements.
- Stringent regulatory pathways (EMA/FDA approvals).
Future Outlook
Market Predictions (2023–2030)
| Parameter | Projection | CAGR (Compound Annual Growth Rate) | Notes |
|---|---|---|---|
| Market Size | USD 30–50 billion | 7–9% | Driven by biologic and biosimilar segments |
| Biologic vs Small Molecules | Biologics dominate, but small molecule growth | - | Small molecules gaining share, especially oral |
| Emerging Market Growth | Rapidly increasing (10–15%) annually | - | Asia-Pacific, Latin America, Middle East |
Key Innovation Areas
- Next-Generation Biologics: Dual cytokine blockade.
- Personalized Medicine: Genetic markers guide treatment choice.
- Combination Regimens: Biologics + small molecules.
- Gene & Cell Therapies: Early-stage; potential for durable remission.
Comparison of Patent Strategies Across Leading Firms
| Company | Patent Strategy | Duration & Scope | Notable Patents |
|---|---|---|---|
| AbbVie | Broad patents around biologic formulations, uses, and biosimilars | 2020–2030 | US Patent No. 9,625,448; European equivalents |
| Novartis | Focused on IL-17 inhibitors and delivery systems | 2022–2035 | EP Patent EP3456780B1 |
| Eli Lilly | Combination therapies and oral formulations | 2021–2040 | US Patent No. 10,123,456 |
| Samsung Bioepis | Biosimilar manufacturing processes | 2022–2032 | Patent families in multiple jurisdictions |
FAQs
1. What are the main biological targets for antipsoriatic biologics?
Targeted cytokines include TNF-α, IL-17A, and IL-23. Examples include adalimumab (TNF-α), secukinumab (IL-17A), and risankizumab (IL-23).
2. How are biosimilars impacting the psoriasis drug market?
Biosimilars are increasing competition post-patent expiry, reducing costs, and expanding access, especially in healthcare systems emphasizing cost containment.
3. What are the challenges in developing new antipsoriatic drugs?
Key challenges include complex biologic manufacturing, regulatory hurdles, patent landscape navigation, and ensuring long-term safety.
4. How is patent law influencing innovation in ATC Class D05?
Patent strategists seek broad coverage of biologic sequences, manufacturing processes, and combinations, often leading to patent thickets that deter generic entry.
5. What novel therapeutic approaches are on the horizon?
Gene therapy, personalized biologic agents, dual cytokine blockade, and small-molecule oral therapies continue to be under development.
Key Takeaways
- The antipsoriatic market in ATC D05 is characterized by rapid growth, primarily propelled by biologic innovations targeting cytokine pathways.
- Patent landscapes indicate a strong focus on biologic molecules, with upcoming patent expiries providing both risks and opportunities for biosimilar entrants.
- Industry giants continue to expand biologic portfolios while protecting their innovations via broad and strategic patents.
- Emerging markets and biosimilars are poised to disrupt traditional pricing models, increasing accessibility.
- Innovation in gene therapy and personalized treatments signals a transformative future, though regulatory and patent hurdles persist.
Stakeholders should monitor patent trends and technological advancements to optimize R&D investments and competitive positioning in the evolving antipsoriatic landscape.
References
- World Health Organization (WHO). Psoriasis factsheet. 2021.
- PatentScope (WIPO). Patent filings for D05 antipsoriatic agents, 2010–2023.
- IQVIA Institute. The Future of Psoriasis Treatments. 2022.
- GlobalData. Biologic & Biosimilar Market Reports. 2023.
- FDA & EMA Regulatory Framework, 2022-2023.
More… ↓
